Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion (CHEER)
|ClinicalTrials.gov Identifier: NCT01186614|
Recruitment Status : Unknown
Verified March 2014 by Ms. Rowan Frew, Bayside Health.
Recruitment status was: Recruiting
First Posted : August 23, 2010
Last Update Posted : March 10, 2014
Sudden out-of-hospital cardiac arrest (OHCA) is a leading cause of death in Australia. The most common cause of OHCA is a heart attack. The current treatment of OHCA is resuscitation by ambulance paramedics involving CPR, electrical shocks to the heart, and injections of adrenaline. In more than 50% of cases, paramedics are unable to start the heart and the patient is declared dead at the scene. Patients with OHCA who do not respond to paramedic resuscitation are not routinely transported to hospital because it is hazardous for paramedics to undertake rapid transport whilst administering chest compressions and there is currently no additional therapy available at the hospital that would assist in starting the heart.
However, a number of recent developments suggest that there may be a new approach to the resuscitation of this group of patients who would otherwise die.
Firstly, Ambulance Victoria have recently introduced portable battery powered machines that allow chest compressions to be safely and effectively delivered during emergency ambulance transport.
Second, The Alfred ICU will shortly be implementing a new protocol whereby the patient in cardiac arrest can immediately be placed on a heart-lung machine. This is known as extra-corporeal membrane oxygenation (ECMO).
Third, the brain can now be much better protected against damage due to lack of blood flow using therapeutic hypothermia which is the controlled lowering of body temperature from 37°C to 33°C. Clinical trials have demonstrated that this significantly decreases brain damage after OHCA.
Finally, The Alfred Cardiology service has an emergency service for reopening the blocked artery of the heart in patients who present with a sudden blockage of the heart arteries. This is currently not used in patients without a heart beat because of the technical difficulty of undertaking this procedure with chest compressions being undertaken.
This study proposes for the first time to implement all the above interventions when patients have failed standard resuscitation after OHCA. When standard resuscitation has proved futile, the patient will be transported to The Alfred with the mechanical chest compression device, cooled to 33°C, placed on ECMO, and then transported to the interventional cardiac catheter laboratory. The patient will then receive therapeutic hypothermia for 24 hours. Subsequent management will follow the standard treatment guidelines of The Alfred Intensive Care Unit.
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Arrest||Device: Automated CPR Device: ECMO Procedure: Coronary angiography Procedure: Therapeutic Hypothermia||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||July 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: Novel treatment paradigm
treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
Device: Automated CPR
Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
Other Name: Zoll AutopulseDevice: ECMO
Insertion of peripheral VA ECMOProcedure: Coronary angiography
Coronary angiography and intervention where necessary will be performed following ECMO insertionProcedure: Therapeutic Hypothermia
Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
- Survival to hospital discharge [ Time Frame: At hospital discharge ]
- Neurologic recovery [ Time Frame: At discharge ]Assessed by cerebral performance category
- Time until ECMO insertion [ Time Frame: On admission ]
- neurologic biomarkers [ Time Frame: Day 3 ]neuron-specific enolase and S100β
- Cardiac recovery [ Time Frame: Days 1, 3, 5 ]measured by echocardiography and cardiac biomakers including troponin, CK and BNP
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01186614
|Contact: Stephen A bernard, MBBS MDfirstname.lastname@example.org|
|Contact: Dion A Stub, MBBSemail@example.com|
|Melbourne, Victoria, Australia, 3161|
|Contact: Stephen Bernard, MBBS MD 90762000|
|Principal Investigator: Stephen A Bernard, MBBS MD|
|Sub-Investigator: Dion A Stub, MBBS|
|Sub-Investigator: Vincent Pellegrino, MBBS|
|Sub-Investigator: Lisen Hockings, MBBS|
|Sub-Investigator: Matthew Reid, RN|
|Sub-Investigator: David M Kaye, MBBS PhD|
|Sub-Investigator: Stephen J Duffy, MBBS PhD|
|Sub-Investigator: Peter Cameron, MBBS MD|
|Sub-Investigator: De Villiers Smit, MBBS|
|Ambulance Victoria||Not yet recruiting|
|Melbourne, Victoria, Australia|
|Contact: Karen Smith, BSc PhD 9840 3752 firstname.lastname@example.org|
|Sub-Investigator: Karen Smith, BSc PhD|
|Sub-Investigator: Tony Walker, HlthSci MICA|
|Principal Investigator:||Stephen A Bernard, MBBS MD||The Alfred|